Constitutive activation of STAT3 in Sézary syndrome is independent of SHP-1
- 5 August 2011
- journal article
- research article
- Published by Springer Nature in Leukemia
- Vol. 26 (2) , 323-331
Abstract
Constitutive and persistent activation of STAT3 has been implicated in the pathogenesis of many malignancies. Studies of CTCL cell lines have previously suggested that aberrant activation of STAT3 is mediated via silencing of the negative regulator SHP-1 by promoter methylation. In this study of ex vivo tumour cell populations from 18 Sézary syndrome (SS) patients, constitutive phosphorylation of STAT3, JAK1 and JAK2 was present in all patients, but was absent in comparative CD4+ T-cells from healthy controls. Furthermore, no loss or significant difference in SHP-1 expression was observed between patients and healthy control samples. Methylation-specific PCR analysis of the SHP-1 CpG island in 47 SS patients and 11 healthy controls did not detect any evidence of methylation. Moreover, small interfering RNA knockdown of SHP-1 had no effect on phosphorylation of STAT3. In contrast, treatment of SS tumour cells with the pan-JAK inhibitor pyridone 6 led to downregulation of phosphorylated STAT3 (pSTAT3), its target genes and induction of apoptosis. No evidence for common JAK1/JAK2-activating mutations was found. These data demonstrate that constitutive activation of STAT3 in SS is not due to the loss of SHP-1, but is mediated by constitutive aberrant activation of JAK family members.Keywords
This publication has 55 references indexed in Scilit:
- JAK3: A two-faced player in hematological disordersThe International Journal of Biochemistry & Cell Biology, 2009
- JAK mutations in high-risk childhood acute lymphoblastic leukemiaProceedings of the National Academy of Sciences, 2009
- Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation modelsBlood, 2009
- Janus kinases in immune cell signalingImmunological Reviews, 2009
- Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemiaJournal of Experimental Medicine, 2008
- STAT3 as a target for inducing apoptosis in solid and hematological tumorsCell Research, 2008
- The BCL-2 protein family: opposing activities that mediate cell deathNature Reviews Molecular Cell Biology, 2008
- Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFκBGenes & Development, 2007
- Lack of Suppressive CD4+CD25+FOXP3+ T Cells in Advanced Stages of Primary Cutaneous T-Cell LymphomaJournal of Investigative Dermatology, 2006
- The STATs of cancer — new molecular targets come of ageNature Reviews Cancer, 2004